风险评估与缓解策略时代的致畸药物产前暴露
基于美国商业保险索赔数据库2006—2017年3,445,612例妊娠的时间序列研究,评估明确致畸药与潜在致畸药的产前暴露流行率。明确致畸药暴露由每100例妊娠1.86降至1.24,潜在致畸药暴露由3.40%升至5.33%,受风险评估与缓解策略约束的药物仅贡献15.1/10万妊娠的暴露。
要点
- 明确致畸药产前暴露由2006年每100例妊娠1.86降至2017年1.24。
- 潜在致畸药产前暴露由3.40%升至5.33%,作者呼吁更多评估。
- 受风险评估与缓解策略约束药物暴露为每10万妊娠15.1例,负担小。
核心结论
- 过去十年间每16例妊娠中仍有超过1例胎儿暴露于致畸药物。
- 受风险评估与缓解策略约束的药物因背景使用率低、育龄女性妊娠患病率低,仅造成较小的产前暴露负担。
- 明确致畸药暴露率下降令人鼓舞,但潜在致畸药产前暴露上升,作者呼吁更多评估。
研究设计与样本
- 基于美国全国私人保险索赔数据库(IBM MarketScan)构建2006—2017年妊娠时间序列。
- 妊娠结局、孕龄和妊娠起点采用既往验证的算法确定。
- 采用致畸信息服务和临床药理学数据库识别明确致畸药(n=141)和潜在致畸药(n=65)。
- 排除风险有争议的药物,包括苯二氮䓬类、他汀类、四环素类、性激素、不孕治疗和促性腺激素释放激素类似物。
- 产前暴露定义为至少1次处方配药或涉及明确致畸风险(含12种有「当前或已中止」风险评估与缓解策略的药物)或潜在致畸风险药物给药的医疗就诊。
主要发现
- 队列纳入3,445,612例妊娠(2,532,444例活产分娩)。
- 明确致畸药产前暴露由2006年每100例妊娠1.86降至2017年1.24。
- 潜在致畸药产前暴露由3.40%升至5.33%。
- 受风险评估与缓解策略约束药物的产前暴露为每10万妊娠15.1例。
- 使用这些治疗的育龄女性中,风险评估与缓解策略药物产前暴露为0.14%,而任何明确致畸药为0.36%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prevention of prenatal exposures to teratogenic drugs is a significant clinical and public health concern. With the enactment of the US Food and Drug Administration Amendments Act in 2007, the US Food and Drug Administration has begun to require manufacturers to implement Risk Evaluation and Mitigation Strategies to prevent prenatal exposures. Among 12 risk evaluation and mitigation strategy drugs, several had predecessor risk mitigation plans (eg, isotretinoin) and some were newly required (eg, mycophenolate). Only a small proportion of teratogenic drugs are currently subject to Risk Evaluation and Mitigation Strategies, and the extent of prenatal exposure to the universe of teratogenic drugs compared with drugs subject to Risk Evaluation and Mitigation Strategies is unknown. Moreover, the effectiveness of such advanced risk mitigation programs in preventing prenatal exposure is not clear. OBJECTIVE: This study aimed to characterize the epidemiology of prenatal exposures to definite and potential teratogens during the risk evaluation and mitigation strategy era. STUDY DESIGN: We constructed a time-series of pregnancies identified from a national private insurance claims database (IBM MarketScan) to estimate prenatal exposures to teratogenic drugs (2006-2017). Pregnancy outcomes, gestational age, and the onset of pregnancy were determined with previously validated algorithms. The Teratology Information Service and Clinical Pharmacology databases were used to identify drugs with definite (n=141) or potential (n=65) teratogenic effects, and drugs with debatable risks such as benzodiazepines, statins, tetracyclines, sex hormones, infertility treatments, and gonadotropin-releasing hormone analogs were excluded. We defined prenatal exposure as ≥1 prescription fill or medical encounter involving administration of drugs with a definite teratogenic risk (including 12 for which there is a "current or discontinued" risk evaluation and mitigation strategy) or a potential teratogenic risk. We evaluated secular trends and modeled the effects of age, preconception exposure, and state healthcare quality rankings on prenatal exposure, adjusting for demographic factors and clinical conditions. RESULTS: The cohort included 3,445,612 pregnancies (2,532,444 live deliveries). Prenatal exposures to definite teratogens decreased slightly during the study years from 1.86 to 1.24 per 100 pregnancies between 2006 and 2017, whereas exposure increased for potential teratogens from 3.40% to 5.33%. Prenatal exposure prevalences were higher during the first trimester and for pregnancies that ended in nonlive outcomes. Drugs subject to Risk Evaluation and Mitigation Strategies had low background utilization and contributed to a small proportion of prenatal exposures (15.1 per 100,000 pregnancies). We also observed fewer prenatal exposures to risk evaluation and mitigation strategy drugs among women of childbearing age who used these treatments (0.14% vs 0.36% for any definite teratogen). Age extremes and low state-level healthcare quality rankings were independent predictors of prenatal exposure. CONCLUSION: Fetuses in more than 1 in 16 pregnancies continued to be exposed to teratogenic drugs during the past decade. Drugs with Risk Evaluation and Mitigation Strategies imposed a small burden of prenatal exposure because of the low background utilization rates and lower pregnancy prevalence among women of childbearing age who used these drugs. Although the declining exposure rates to teratogenic drugs with definite risk are encouraging, the rising prenatal exposure to drugs with potential risk calls for more assessments. Future research is needed to elucidate the health outcomes of fetuses exposed to potential risk drugs, understand the effectiveness of risk evaluation and mitigation strategy programs, and prioritize teratogenic drugs for advanced risk mitigation.
引用
- Sarayani A, Albogami Y, Thai TN, et al. Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies. Am J Obstet Gynecol. 2022. PMID: 35032444. doi:10.1016/j.ajog.2022.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。